In short
This article summarizes several clinical trials investigating the use of PF-07220060 Monohydrate, a novel drug, for treating advanced breast cancer. These studies aim to evaluate the safety, efficacy, and optimal dosing of PF-07220060 alone and in combination with other therapies for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The trials explore various treatment regimens and patient populations to determine the most promising approaches for improving outcomes in this difficult-to-treat cancer type.
At a glance
- Study Drug
- PF-07220060 Monohydrate
- Cancer Types
- Primarily HR-positive, HER2-negative advanced or metastatic breast cancer; some trials include other solid tumors
- Study Phases
- Phase 1, Phase 1b, Phase 2, Phase 3
- Treatment Combinations
- PF-07220060 as monotherapy and in combination with fulvestrant, letrozole, enzalutamide, and PF-07104091
- Key Objectives
- Safety, tolerability, efficacy, pharmacokinetics, optimal dosing
- Primary Endpoints
- Progression-free survival, overall survival, objective response rate, Ki-67 expression changes
- Secondary Endpoints
- Duration of response, safety assessments, quality of life measures, biomarker analyses
- Patient Populations
- Adults with advanced solid tumors, focus on breast cancer patients who have progressed on prior therapies
- Administration
- Oral tablets or film-coated tablets, various dosing schedules
- Novel Aspects
- Evaluation in neoadjuvant setting, combination with newer therapies, biomarker-driven assessments
What is PF-07220060?
PF-07220060 MONOHYDRATE is an investigational drug being developed by Pfizer for the treatment of advanced breast cancer and other solid tumors. It is a new type of medication that is taken orally in the form of tablets or film-coated tablets.
How does it work?
PF-07220060 is believed to work by inhibiting certain proteins called cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6. These proteins play an important role in regulating cell growth and division. By blocking their activity, PF-07220060 may be able to slow down or stop the growth of cancer cells.
What conditions does it treat?
PF-07220060 is primarily being studied for the treatment of:
- Hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer: This is a type of breast cancer that has spread beyond the breast to other parts of the body and is driven by hormones like estrogen or progesterone.
- Prostate cancer: Specifically, metastatic castration-resistant prostate cancer (mCRPC).
- Other advanced solid tumors, including:
- Non-small cell lung cancer (NSCLC)
- Colorectal cancer (CRC)
- Liposarcoma
- Tumors with confirmed CDK4 or CCND1 amplification
Clinical Trials
PF-07220060 is currently being evaluated in several clinical trials:
- Study C4391022: A Phase 3 study comparing PF-07220060 plus fulvestrant to investigator's choice of therapy in patients with HR+/HER2- advanced/metastatic breast cancer who have progressed after prior CDK4/6 inhibitor therapy.
- Study C4891026: A Phase 1b/2 study investigating the combination of PF-07220060 with vepdegestrant (ARV-471/PF-07850327) in patients with ER+/HER2- advanced or metastatic breast cancer.
- Study C4391002: A Phase 1b/2 study evaluating PF-07220060 in combination with PF-07104091 plus endocrine therapy in patients with advanced solid tumors, including HR+/HER2- breast cancer.
- Study C4391001: A Phase 1/2a study assessing PF-07220060 as a single agent and in combination with other therapies in patients with various advanced solid tumors.
- Study C4391025: A Phase 2 study comparing PF-07220060 plus letrozole to letrozole alone in postmenopausal women with HR+/HER2- breast cancer in the neoadjuvant setting.
Potential Benefits
Based on the ongoing clinical trials, PF-07220060 may offer several potential benefits:
- Improved progression-free survival (PFS) in patients with advanced breast cancer
- Potential to overcome resistance to prior CDK4/6 inhibitor therapy
- Combination potential with other targeted therapies and endocrine therapies
- Oral administration, which may be more convenient for patients compared to intravenous treatments
- Possible efficacy in multiple types of solid tumors
Side Effects and Safety
As PF-07220060 is still in clinical trials, the full safety profile is not yet established. However, some potential side effects and safety considerations based on the ongoing studies include:
- Changes in blood cell counts (e.g., decreased white blood cells, platelets, or red blood cells)
- Liver function abnormalities
- Gastrointestinal effects (e.g., nausea, diarrhea)
- Fatigue
- Potential for drug interactions, particularly with medications that affect certain liver enzymes (CYP3A4/5 and UGT2B7)
It's important to note that the safety and tolerability of PF-07220060 are being closely monitored in all ongoing clinical trials.
Future Research
The development of PF-07220060 is ongoing, with several clinical trials in progress. Future research aims to:
- Determine the most effective dosing regimens and combinations with other therapies
- Evaluate its efficacy in different types of solid tumors
- Assess its potential in earlier stages of breast cancer treatment, such as the neoadjuvant setting
- Further characterize its safety profile and long-term effects
- Identify biomarkers that may predict which patients are most likely to benefit from the treatment
As research progresses, more information about PF-07220060 and its potential role in cancer treatment will become available. Patients interested in learning more about this investigational drug should speak with their healthcare providers about the latest developments and potential clinical trial opportunities.